Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Opus Genetics OCF Yield % Related Terms
Opus Genetics OCF Yield % Historical Data
* Premium members only.
The historical data trend for Opus Genetics's OCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:R3X1 vs PALI, VSTM, GALT: OCF Yield % Comparison
For the Biotechnology subindustry, Opus Genetics's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Opus Genetics OCF Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Opus Genetics's OCF Yield % distribution charts can be found below:
* The bar in red indicates where Opus Genetics's OCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Opus Genetics (STU:R3X1) has a OCF Yield % of -15.33 as of Jul. 26, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Opus Genetics and its competitors. According to the industry distribution chart, Opus Genetics ranks #889 out of 1410 companies in the Biotechnology industry, placing it in the top 63%.
Is Opus Genetics' OCF Yield % too high?
Opus Genetics' current OCF Yield % is -15.33. Based on the distribution chart, Opus Genetics ranks #889 out of 1410 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Opus Genetics has a GF Score™ of 29/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Opus Genetics' OCF Yield % compare to PALI and VSTM?
According to the Biotechnology industry distribution chart, Opus Genetics ranks #889 out of 1410 companies for OCF Yield %. This places Opus Genetics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Biotechnology company?
A good OCF Yield % depends on the Biotechnology industry context. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Opus Genetics and its competitors. Opus Genetics's current OCF Yield % is -15.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Opus Genetics stock overvalued right now?
Based on GuruFocus' analysis, Opus Genetics (STU:R3X1) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.31, compared to a current price of €2.68 — trading 764.5% above its estimated fair value. The current OCF Yield % is -15.33. Opus Genetics' overall GF Score™ is 29/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For Opus Genetics (STU:R3X1), the current OCF Yield % is -15.33 as of Jul. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Opus Genetics (STU:R3X1) Overvalued in 2026?
Based on GuruFocus' analysis, Opus Genetics stock appears to be overvalued.
The current stock price of €2.68 is trading 764.5% above its estimated GF Value™ of €0.31.
GuruFocus considers Opus Genetics to be Significantly Overvalued.
Key valuation signals for STU:R3X1:
OCF Yield %: -15.33
GF Value™: €0.31 vs. price of €2.68 (764.5% above fair value)
No single metric tells the full story. See the STU:R3X1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes seven adeno-associated virus (AAV)-based programs, led by OPGx-LCA5 for LCA5-related mutations and OPGx-BEST1 for BEST1-related retinal degeneration, with additional candidates targeting RHO, CNGB1, RDH12, NMNAT1, and MERTK. The company operates in one operating segment, which is the business of developing products related to vision performance and health.
29GF Score
Get the complete analysis for STU:R3X1
OCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:R3X1 has been successfully added to your 
